Slide 1: Fourth Quarter 2024 Earnings
Fourth Quarter 2024 Earnings January 31, 2025
Slide 2: Safe Harbor
Safe Harbor This presentation contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial
Slide 3: Key Takeaways
Key Takeaways Innovation Transformation Performance New partnerships with Stronger organic growth Announced new operational & Genomics England and driven by Life Sciences financial segmentation Element Biosciences Reagents & Software beginning in FY25 Launched new Strong synergy realization Investor
Slide 4: 4Q24 Revenue Highlights
4Q24 Revenue Highlights Segments Geographic Product Mix Diagnostics Life Sciences AMERICAS APAC EU RECURRING NON-RECURRING -HSD +MSD +MSD $0.7 B +MSD +MSD $0.7 B +HSD $0.7 B +LSD Reconciliations to the most directly comparable GAAP measure for the non-GAAP terms presented above are provided on our w
Slide 5: 2024 Revenue Highlights
2024 Revenue Highlights Segments Geographic Product Mix Diagnostics Life Sciences AMERICAS APAC EU RECURRING NON-RECURRING -DD +LSD +MSD $2.76 B -LSD +LSD $2.76 B +MSD $2.76 B -LSD Reconciliations to the most directly comparable GAAP measure for the non-GAAP terms presented above are provided on our
Slide 6: 4Q24 Financial Results
4Q24 Financial Results ADJUSTED REVENUE ADJUSTED OP MARGIN ADJUSTED EPS FREE CASH FLOW $730M 30.3% $1.42 $151M +5% y/y +280bps y/y +14% y/y $578M FY24 Organic: Adj. Gross Margin: Adj. Tax Rate: FY24 FCF % Adj. NI +6% | M&A: 0% | FX: -1% 61.4% | +120bps y/y 15.7% 96% Adj. Net Interest & Other: Exclud
Slide 7: 2024 Financial Results
2024 Financial Results ADJUSTED REVENUE ADJUSTED OP MARGIN ADJUSTED EPS FREE CASH FLOW $2,756M 28.3% $4.90 $578M FCF % Adj. NI +0% y/y +30bps y/y +6% y/y 96% Organic: Adj. Gross Margin: Adj. Tax Rate: Excludes AES inflows of an +1% | M&A: 0% | FX: 0% 61.3% | -10bps y/y 18.4% additional $157M YTD Adj
Slide 8: Life Sciences
Life Sciences Product REVENUE AJUSTED OP MARGINS REAGENTS INSTRUMENTS SOFTWARE 5% Organic Growth 38.9% -HSD +200bps y/y Reported: 5% | M&A: 0% | FX: 0% $336 M • +MSD growth from Pharma/Biotech, +LSD growth from Academic/Gov’t +MSD 4Q24 revenue +DD • +MSD growth in reagents; -HSD instruments decline
Slide 9: Diagnostics
Diagnostics End Market REVENUE AJUSTED OP MARGINS IMMUNODX REPRODUCTIVE APPLIED HEALTH GENOMICS 6% Organic Growth 25.0% Reported: 4% | M&A: 0% | FX: -1% +390 bps y/y +HSD +MSD $393 M • +MSD ImmunoDX globally and in China 4Q24 revenue • +HSD Reproductive Health globally; +MSD in China +LSD • +LSD App
Slide 10: 2025 Financial Guidance
2025 Financial Guidance REVENUE $2.80B - $2.85B Reported: 1.5% to 3.5% Organic: 3% to 5% FX: -1.5%, M&A: 0% ADJUSTED OP. MARGIN 28.5-28.7% ADJUSTED EPS $4.90 - $5.00 Adj. Net interest expense, other: ~$70M Adjusted tax rate: ~20% Average diluted share count: 120.0M 10
Slide 11: Revvity.com
Revvity.com